Literature DB >> 6997332

Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man.

S L Swartz, G H Williams, N K Hollenberg, L Levine, R G Dluhy, T J Moore.   

Abstract

Captopril is a potent hypotensive agent whose efficacy has hitherto been attributed to its ability to alter either angiotensin II formation or kinin degradation. Our purpose was to examine captopril's acute effect on prostaglandin production, because changes in neither the renin-angiotensin nor the kallikrein-kinin systems appear adequate to account for the fall in arterial pressure. The plasma levels of angiotensin II, kinins, and prostaglandins were determined in response to increasing doses (5, 12.5, and 25 mg) of captopril and these responses were compared with the change in arterial pressure observed in nine supine normal male subjects studied on both a high (200 meq) and low (10 meq) sodium intake.Captopril significantly (P < 0.01) increased the levels of the 13,14-dihydro-15-keto metabolite of prostaglandin E(2) (PGE(2)-M), a potent vasodilator, with similar responses being observed on both a high and a low sodium intake. No significant changes in the plasma levels of 6-keto-prostaglandin F (1)alpha, or thromboxane B(2), the stable products of prostacyclin and thromboxane A(2), respectively, occurred. The depressor response to captopril correlated with the change in PGE(2)-M (r = 0.52, t = 5.44, P < 0.0001). On the other hand, although significant (P < 0.02) decrements in angiotensin II and increments in plasma kinins accompanied the hypotensive response in sodium-restricted subjects, in sodium-loaded subjects where the renin-angiotensin system was suppressed, no change in angiotensin II, and only a modest change in kinins was noted, even though significant (P < 0.01) decrements in diastolic blood pressure occurred (-10+/-2 mm Hg).Thus, changes in depressor prostaglandin production can better account for the hypotensive response to captopril, thereby extending to yet another vasoactive system an influence by this class of drugs and providing a new approach to dissecting the abnormality in the control of vascular tone in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6997332      PMCID: PMC371462          DOI: 10.1172/JCI109788

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Specific stimulation and inhibition of renal prostaglandin release by angiotensin analogs.

Authors:  P Needleman; A H Kauffman; J R Douglas; E M Johnson; G R Marshall
Journal:  Am J Physiol       Date:  1973-06

2.  Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin.

Authors:  J W Aiken; J R Vane
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

3.  Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma.

Authors:  R L Emanuel; J P Cain; G H Williams
Journal:  J Lab Clin Med       Date:  1973-04

4.  Prostaglandin release from the human umbilical artery in vitro.

Authors:  T Tuvemo; L Wide
Journal:  Prostaglandins       Date:  1973-11

5.  Analysis of prostaglandin F 2 and metabolites in blood during constant intravenous infusion of prostaglandin F 2 in the human female.

Authors:  F Beguin; M Bygdeman; K Gréen; B Samuelsson; M Toppozada; N Wiqvist
Journal:  Acta Physiol Scand       Date:  1972-11

6.  The simultaneous measurement of aldosterone, cortisol, and corticosterone in human peripheral plasma by displacement analysis.

Authors:  R H Underwood; G H Williams
Journal:  J Lab Clin Med       Date:  1972-05

7.  A radioimmunoassay for bradykinin in plasma and synovial fluid.

Authors:  R C Talamo; E Haber; K F Austen
Journal:  J Lab Clin Med       Date:  1969-11

8.  Direct effects of prostaglandin on renal function and renin release in anesthetized dog.

Authors:  A J Vander
Journal:  Am J Physiol       Date:  1968-02

9.  Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture.

Authors:  P Y Wong; R C Talamo; G H Williams; R W Colman
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

10.  Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.

Authors:  N K Hollenberg; W R Chenitz; D F Adams; G H Williams
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  49 in total

Review 1.  Nifedipine interactions in hypertensive patients.

Authors:  A Salvetti; A Magagna; B Abdel-Haq; M Lenzi; R Giovannetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

3.  Renal haemodynamics during hyperchloraemia in the anaesthetized dog: effects of captopril.

Authors:  C S Wilcox
Journal:  J Physiol       Date:  1988-12       Impact factor: 5.182

Review 4.  Heart failure therapy at the turn of the century.

Authors:  S Goldstein
Journal:  Heart Fail Rev       Date:  2001-01       Impact factor: 4.214

5.  The effect of captopril (SQ14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit.

Authors:  F Broughton Pipkin; E M Symonds; S R Turner
Journal:  J Physiol       Date:  1982-02       Impact factor: 5.182

6.  Captopril(SQ 14,225): in vitro and in vivo influence on the proliferative response of rat lymphocytes.

Authors:  L Binderup; E Bramm; E Arrigoni-Martelli
Journal:  Experientia       Date:  1982-03-15

7.  Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment.

Authors:  S Rich; J Martinez; W Lam; K M Rosen
Journal:  Br Heart J       Date:  1982-09

Review 8.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 9.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.

Authors:  B Waeber; L Juillerat-Jeanneret; J F Aubert; M Schapira; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

10.  Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.

Authors:  A Overlack; K O Stumpe; M Kühnert; R Kolloch; C Ressel; I Heck; F Krück
Journal:  Klin Wochenschr       Date:  1981-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.